Loading...

NKTR NEKTAR THERAPEUTICS Product Launches 8-K Filing

NKTR

NKTR

NEKTAR THERAPEUTICS

(NKTR)

2025 8-K

Management Change

New Clinical Data

Financial Results

New Clinical Data

Financial Statements

Equity Offerings

Compliance Issues

Product Expansion

Reverse Stock Split

Reverse Stock Split

Financial Statements

Financial Results

Clinical Trial Agreement

Management Change

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results

Compliance with Minimum Bid...

Amendment to Purchase Agree...

Securities Purchase Agreement

Stock Repurchase

Earnings Reports

Financial Results Announcement

Financial Results Announcement

Disclosure and Other Events

Management Change

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Agreement

Restructuring Plan and CFO ...

External Links:

On September 18, 2025, Nektar Therapeutics announced new data from the ongoing REZOLVE-AD Phase 2b study of their drug rezpegaldesleukin. This filing presents key findings and insights related to the treatment of atopic dermatitis based on the study results.

AI Assistant

NEKTAR THERAPEUTICS

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.